{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-010227","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2022-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.211574+00:00","generated_at":"2026-06-24T23:29:31.474311+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.15,"confidence":"high","headline":"TG Therapeutics shareholders reject advisory say-on-pay and annual frequency vote","bullets":["Proposal 4 (advisory vote on executive compensation) defeated: 25.8M for, 61.2M against.","Proposal 5 (advisory vote on frequency): 66.9M voted for annual, but board will retain triennial frequency.","Director Yann Echelard and Daniel Hume each received only ~31.5% support, Sagar Lonial got 26.4%.","Shareholders approved 2022 Incentive Plan (53.9M for, 33.3M against) and ratified KPMG (114.0M for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-010227","json":"https://secwatch.observer/filing/0001558370-22-010227.json","markdown":"https://secwatch.observer/filing/0001558370-22-010227.md","text":"https://secwatch.observer/filing/0001558370-22-010227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022010227/0001558370-22-010227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022010227/tgtx-20220616x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:29:31.474311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}